Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Community and Patient Preference Research

Status: Completed

Conditions: Allergic Rhinitis

Treatments: Other: Observational

Study type: Observational

Funder types: Industry

Identifiers

NCT05146206

20210902_2

Details and patient eligibility

About

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

Full description

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes.

The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.

Enrollment: 426 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:

• Patients above 18 years old
• Fluent in English
• Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment
• Willing and able to provide consent to participate

Exclusion criteria

• Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)
• Are employed by a pharmaceutical company (to avoid conflict of interest)
• Are employed by a vaccine company (to avoid conflict of interest)
• Do not have access to the internet (to ensure validity of the data)
• Are unable to read and understand English (to ensure validity of the data)

Trial design

426 participants in 2 patient groups

Patients on RYALTRIS

Description:

Patients who are currently using RYALTRIS nasal spray.

Treatment:

Other: Observational

Patients on DYMISTA

Description:

Patients who are currently using DYMISTA nasal spray.

Treatment:

Other: Observational